Febrile Neutropenia - Pipeline Review, H2 2016

  • ID: 3946409
  • Report
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Apotex Inc.
  • Biogenomics Limited
  • Coherus BioSciences, Inc.
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • USV Pvt Ltd
  • MORE
Febrile Neutropenia - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides an overview of the Febrile Neutropenia (Hematological Disorders) pipeline landscape.

Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of chemotherapy when it is myelosuppressive (suppresses the bone marrow from producing blood cells). Symptoms include fever, flu-like symptoms, shaking chills, severe night sweats, nausea and vomiting, especially with fever, tenderness, redness, swelling, pain or discharge at the site of a catheter and headache or neck stiffness.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Febrile Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Febrile Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 1, 2, 2, 1 and 3 respectively for Febrile Neutropenia.

Febrile Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Febrile Neutropenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Febrile Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Febrile Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Febrile Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Febrile Neutropenia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Febrile Neutropenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Febrile Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Apotex Inc.
  • Biogenomics Limited
  • Coherus BioSciences, Inc.
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • USV Pvt Ltd
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Febrile Neutropenia Overview

Therapeutics Development

Pipeline Products for Febrile Neutropenia - Overview

Febrile Neutropenia - Therapeutics under Development by Companies

Febrile Neutropenia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Febrile Neutropenia - Products under Development by Companies

Febrile Neutropenia - Companies Involved in Therapeutics Development

Apotex Inc.

BeyondSpring Pharmaceuticals, Inc.

Biogenomics Limited

Coherus BioSciences, Inc.

Dr. Reddy's Laboratories Limited

Richter Gedeon Nyrt.

Sandoz International GmbH

Therapeutic Proteins International, LLC

USV Pvt Ltd

Febrile Neutropenia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

EC-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Febrile Neutropenia - Dormant Projects

Febrile Neutropenia - Product Development Milestones

Featured News & Press Releases

Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study

Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study

Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701

Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program

Dec 08, 2015: EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim

Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA

Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Febrile Neutropenia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Febrile Neutropenia - Pipeline by Apotex Inc., H2 2016

Febrile Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016

Febrile Neutropenia - Pipeline by Biogenomics Limited, H2 2016

Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016

Febrile Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016

Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016

Febrile Neutropenia - Pipeline by Sandoz International GmbH, H2 2016

Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016

Febrile Neutropenia - Pipeline by USV Pvt Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Febrile Neutropenia - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Febrile Neutropenia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Apotex Inc.
BeyondSpring Pharmaceuticals, Inc.
Biogenomics Limited
Coherus BioSciences, Inc.
Dr. Reddy's Laboratories Limited
Richter Gedeon Nyrt.
Sandoz International GmbH
Therapeutic Proteins International, LLC
USV Pvt Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll